Details for New Drug Application (NDA): 205431
✉ Email this page to a colleague
NDA 205431 describes CYPROHEPTADINE HYDROCHLORIDE, which is a drug marketed by Actavis Mid Atlantic, Chartwell Molecular, Elysium, Halsey, Morton Grove, Naska, Patrin, Pharm Assoc, Quagen, Rising, Tris Pharma Inc, Am Therap, Appco, Ascot, Beximco Pharms Usa, Chartwell Rx, Duramed Pharms Barr, Heritage Pharma, Kenton, Kv Pharm, Md Pharm, Mountain, Mylan, Novast Labs, Pioneer Pharms, Pliva, Strides Pharma, Superpharm, Vitarine, Watson Labs, and Zydus Pharms, and is included in thirty-nine NDAs. It is available from twenty-three suppliers. Additional details are available on the CYPROHEPTADINE HYDROCHLORIDE profile page.
The generic ingredient in CYPROHEPTADINE HYDROCHLORIDE is cyproheptadine hydrochloride. There are six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the cyproheptadine hydrochloride profile page.
The generic ingredient in CYPROHEPTADINE HYDROCHLORIDE is cyproheptadine hydrochloride. There are six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the cyproheptadine hydrochloride profile page.
Summary for 205431
| Tradename: | CYPROHEPTADINE HYDROCHLORIDE |
| Applicant: | Tris Pharma Inc |
| Ingredient: | cyproheptadine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 205431
Suppliers and Packaging for NDA: 205431
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CYPROHEPTADINE HYDROCHLORIDE | cyproheptadine hydrochloride | SYRUP;ORAL | 205431 | ANDA | Tris Pharma Inc | 27808-099 | 27808-099-01 | 473 mL in 1 BOTTLE, PLASTIC (27808-099-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | 2MG/5ML | ||||
| Approval Date: | Dec 21, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
